trastuzumab
Intravenous Infusion Initial U.S. Approval: 1998

Herceptin is used in the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. It is also used in metastatic breast cancer and in gastric cancer. The patent in 2019 in the United States.

Facts about trastuzumab Intravenous Infusion

Approval Date: 1998
Proprietary Name: On Request
Active Ingredient(s): infliximab
Dosage Forms And Strengths: Multidose vial nominally containing 440 mg Herceptin as a lyophilized, sterile powder.
Company: Roche
Diseases: metastatic breast cancer and in gastric cancer
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import trastuzumab Intravenous Infusion” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

tucatinib tablets,
for oral use Initial U.S. Approval: 2020

Tucatinib tablets is a “used to treat advanced, unresectable or metastatic HER2-positive breast cancer“. TUKYSA Tablets is a “prescription medicine. It is available in “form and strength” Tablets: 50 mg and 150 mg.. TUKYSA Tablets can be obtained in India upon request.

To inquire about the “offer price in India”, “shipping process”, and the “estimated time of availability in India”, please get in touch at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj). with the IPN Delhi healthcare team for further discussion.”

Facts about your medicine

Name: TUKYSA
Active substance: tucatinib
Disease Indications-Breast Cancer
Manufacturer-Seattle Genetics
Usage-Oral
Medicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Swissmedic CH)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)